- Home
- CAN vs FDMT Comparison
CAN vs FDMT Comparison
Compare CAN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | FDMT |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 455.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAN | FDMT |
|---|---|---|
| Price | $0.67 | $7.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $3.56 | ★ $30.33 |
| AVG Volume (30 Days) | ★ 18.5M | 1.2M |
| Earning Date | 11-18-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $422,228,000.00 | $120,000.00 |
| Revenue This Year | $92.55 | $21,181.08 |
| Revenue Next Year | $41.93 | $162.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 83.87 | ★ 605.88 |
| 52 Week Low | $0.53 | $2.24 |
| 52 Week High | $2.47 | $12.34 |
Technical Indicators
Market Signals| Indicator | CAN | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 31.59 |
| Support Level | $0.71 | $7.67 |
| Resistance Level | $0.89 | $11.81 |
| Average True Range (ATR) | 0.06 | 0.73 |
| MACD | -0.00 | -0.27 |
| Stochastic Oscillator | 2.13 | 1.60 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.